Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...
StockStory.org on MSN4d
2 Reasons to Sell TXG and 1 Stock to Buy InsteadWhat a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many ...
Torex Gold Resources Inc. (TSE:TXG – Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$28.99 and ...
Serge Saxonov, the Chief Executive Officer of $TXG, sold 7,942 shares of the company on 02-28-2025 for an estimated $84,393. We received data on the trade from a ...
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...
The market expects 10x Genomics (TXG) to deliver a year-over-year increase ... This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor ...
Hosted on MSN1mon
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses ExpectationsB iotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s full-year revenue guidance of $620 ...
2024 marks the sixth consecutive year production guidance has been achieved Toronto, Ontario--(Newsfile Corp. - January 8, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) ...
TXG) develops single-cell and spatial genomics solutions, enabling researchers to analyze biological systems at high resolution. Free cash flow isn't a prominently featured metric in company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results